Champions Oncology (NASDAQ:CSBR – Get Free Report) and Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.
Analyst Ratings
This is a breakdown of current ratings and price targets for Champions Oncology and Nautilus Biotechnology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
| Nautilus Biotechnology | 1 | 1 | 2 | 1 | 2.60 |
Nautilus Biotechnology has a consensus target price of $3.83, suggesting a potential upside of 76.65%. Given Nautilus Biotechnology’s stronger consensus rating and higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Champions Oncology.
Valuation and Earnings
This table compares Champions Oncology and Nautilus Biotechnology”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Champions Oncology | $60.66 million | 1.01 | -$1.17 million | ($0.08) | -55.00 |
| Nautilus Biotechnology | $36,000.00 | 7,677.70 | -$59.00 million | ($0.46) | -4.72 |
Champions Oncology has higher revenue and earnings than Nautilus Biotechnology. Champions Oncology is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 46.3% of Champions Oncology shares are held by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk & Volatility
Champions Oncology has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500.
Profitability
This table compares Champions Oncology and Nautilus Biotechnology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Champions Oncology | -1.82% | -25.77% | -3.71% |
| Nautilus Biotechnology | N/A | -42.68% | -34.39% |
Summary
Nautilus Biotechnology beats Champions Oncology on 9 of the 15 factors compared between the two stocks.
About Champions Oncology
Champions Oncology is a biotechnology company focused on cancer research and precision oncology. It develops and uses patient-derived tumor models and related technologies to study how cancers respond to treatments. The company provides research services to biopharmaceutical firms developing cancer therapies, including preclinical testing and translational research. It also offers tumor-profiling and treatment-testing services intended to help physicians evaluate potential therapies for individual patients.
About Nautilus Biotechnology
Nautilus Biotechnology develops a platform designed to measure and analyze proteins at scale. Its approach combines technologies such as protein engineering, nanotechnology and computational analysis to help researchers study the proteome—the full set of proteins produced by a cell, tissue or organism. The company’s platform is intended for applications in biological research and drug development, including investigating how proteins relate to health and disease. Nautilus has described its technology as aiming to provide broad, detailed protein measurements that can support research across a range of biological samples.
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
